Brief: Orchid Pharma Enters Into Manufacturing Sublicense Agreement With Global Antibiotic Research & Development Partnership
Sept 12 (Reuters) - Orchid Pharma Ltd ORCD.NS :
* ENTERED INTO MANUFACTURING SUBLICENSE AGREEMENT WITH
GLOBAL
ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP
* AGREEMENT TO MANUFACTURE CEFIDEROCOL, AN ANTIBIOTIC TO
TREAT
CERTAIN GRAM-NEGATIVE INFECTIONS
Source text for Eikon: ID:nBSE3FZshw
Further company coverage: ORCD.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Orchid Pharma
See all newsBrief: Orchid Pharma Approves Enabling Resolution To Explore Fund Raising Via Equity Or Other Securities
Brief: Orchid Pharma To Consider And Evaluate Various Options For Raising Funds
Brief: Orchid Pharma June-Quarter Consol Profit 25.8 Million Rupees
India's Orchid Pharma jumps on pact to commercialize Exblifep in Russia
Refile: INDIA STOCKS-Indian shares set to open lower as US-Iran tensions lift oil prices